Enanta Pharmaceuticals (ENTA) Competitors

$11.07 -0.21 (-1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$11.07 0.00 (0.00%)

As of 04:10 PM Eastern

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

Should you buy Enanta Pharmaceuticals stock or one of its competitors? MarketBeat compares Enanta Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enanta Pharmaceuticals include ArriVent BioPharma (AVBP), Precigen (PGEN), Inhibrx Biosciences (INBX), Ardelyx (ARDX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

ArriVent BioPharma currently has a consensus price target of $43.38, suggesting a potential upside of 42.21%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 83.25%. Given Enanta Pharmaceuticals' higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Enanta Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

ArriVent BioPharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

ArriVent BioPharma has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. ArriVent BioPharma's return on equity of -48.98% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ArriVent BioPharma had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 1 mentions for ArriVent BioPharma and 0 mentions for Enanta Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 1.32 beat Enanta Pharmaceuticals' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ArriVent BioPharma	Positive
Enanta Pharmaceuticals	Neutral

Summary

ArriVent BioPharma and Enanta Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Precigen?

Precigen (NASDAQ:PGEN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Precigen had 3 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Precigen and 0 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.00 beat Precigen's score of -0.57 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Precigen	Negative
Enanta Pharmaceuticals	Neutral

Enanta Pharmaceuticals has higher revenue and earnings than Precigen. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	131.48	-$250.64M	-$1.18	N/A
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

Enanta Pharmaceuticals has a net margin of -89.56% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-646.99%	717.50%	58.48%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

33.5% of Precigen shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 47.1% of Precigen shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Precigen presently has a consensus price target of $12.50, indicating a potential upside of 250.14%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 83.25%. Given Precigen's higher probable upside, equities research analysts plainly believe Precigen is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Precigen beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Inhibrx Biosciences has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enanta Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A
Inhibrx Biosciences	$1.30M	1,005.80	-$140.05M	-$8.39	N/A

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.33, suggesting that its stock price is 233% more volatile than the broader market.

In the previous week, Enanta Pharmaceuticals' average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Inhibrx Biosciences	Neutral

Enanta Pharmaceuticals currently has a consensus price target of $20.29, suggesting a potential upside of 83.25%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 68.29%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Enanta Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

Enanta Pharmaceuticals beats Inhibrx Biosciences on 10 of the 15 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Ardelyx currently has a consensus price target of $15.70, indicating a potential upside of 183.39%. Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 83.25%. Given Ardelyx's stronger consensus rating and higher probable upside, research analysts clearly believe Ardelyx is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ardelyx had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for Ardelyx and 0 mentions for Enanta Pharmaceuticals. Ardelyx's average media sentiment score of 1.06 beat Enanta Pharmaceuticals' score of 0.00 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Positive
Enanta Pharmaceuticals	Neutral

Ardelyx has a net margin of -13.58% compared to Enanta Pharmaceuticals' net margin of -89.56%. Ardelyx's return on equity of -38.11% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Ardelyx has higher revenue and earnings than Enanta Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.36	-$61.60M	-$0.23	N/A
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

Summary

Ardelyx beats Enanta Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Enanta Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Septerna has a net margin of -49.88% compared to Enanta Pharmaceuticals' net margin of -89.56%. Septerna's return on equity of -12.72% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Septerna currently has a consensus price target of $45.00, suggesting a potential upside of 47.98%. Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 83.25%. Given Enanta Pharmaceuticals' higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Septerna had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 0 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.00 beat Septerna's score of -0.03 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Septerna	Neutral
Enanta Pharmaceuticals	Neutral

Septerna has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 4.3% of Septerna shares are owned by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Septerna has higher earnings, but lower revenue than Enanta Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A
Enanta Pharmaceuticals	$65.32M	4.93	-$81.89M	-$2.59	N/A

Summary

Septerna beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTA vs. The Competition

Export

Metric	Enanta Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$328M	$2.96B	$6.49B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.57%
P/E Ratio	-4.27	12.28	20.24	21.95
Price / Sales	4.93	288.30	507.57	108.00
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	3.65	3.83	10.28	6.78
Net Income	-$81.89M	$75.85M	$3.57B	$337.51M
7 Day Performance	-12.63%	-4.52%	-1.43%	-2.72%
1 Month Performance	-27.84%	-5.85%	3.27%	1.87%
1 Year Performance	48.19%	15.31%	23.37%	26.61%

Enanta Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTA Enanta Pharmaceuticals	1.8096 of 5 stars	$11.07 -1.9%	$20.29 +83.2%	+51.0%	$328M	$65.32M	N/A	160
AVBP ArriVent BioPharma	2.5327 of 5 stars	$29.92 -2.5%	$43.38 +45.0%	+29.0%	$1.39B	N/A	N/A	40	Positive News
PGEN Precigen	2.5828 of 5 stars	$3.86 -6.3%	$12.50 +223.8%	+138.7%	$1.38B	$9.68M	N/A	190	High Trading Volume
INBX Inhibrx Biosciences	2.241 of 5 stars	$93.63 -5.7%	$150.00 +60.2%	+525.1%	$1.37B	$1.30M	N/A	166	Gap Up
ARDX Ardelyx	3.0263 of 5 stars	$5.52 -3.7%	$15.70 +184.4%	+51.1%	$1.36B	$427.68M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Summary

How does Enanta Pharmaceuticals compare to Precigen?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Enanta Pharmaceuticals compare to Ardelyx?

Summary

How does Enanta Pharmaceuticals compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enanta Pharmaceuticals (ENTA) Competitors

ENTA vs. AVBP, PGEN, INBX, ARDX, and SEPN

How does Enanta Pharmaceuticals compare to ArriVent BioPharma?

Do analysts prefer AVBP or ENTA?

Which has higher valuation and earnings, AVBP or ENTA?

Which has more risk and volatility, AVBP or ENTA?

Is AVBP or ENTA more profitable?

Do institutionals and insiders hold more shares of AVBP or ENTA?

Does the media refer more to AVBP or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Precigen?

Does the media favor PGEN or ENTA?

Which has preferable earnings & valuation, PGEN or ENTA?

Is PGEN or ENTA more profitable?

Do institutionals & insiders have more ownership in PGEN or ENTA?

Which has more risk & volatility, PGEN or ENTA?

Do analysts prefer PGEN or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Inhibrx Biosciences?

Is ENTA or INBX more profitable?

Do insiders and institutionals believe in ENTA or INBX?

Which has stronger valuation and earnings, ENTA or INBX?

Which has more volatility and risk, ENTA or INBX?

Does the media refer more to ENTA or INBX?

Do analysts prefer ENTA or INBX?

Summary

How does Enanta Pharmaceuticals compare to Ardelyx?

Do analysts recommend ARDX or ENTA?

Do insiders and institutionals have more ownership in ARDX or ENTA?

Does the media prefer ARDX or ENTA?

Is ARDX or ENTA more profitable?

Which has more risk & volatility, ARDX or ENTA?

Which has better valuation and earnings, ARDX or ENTA?

Summary

How does Enanta Pharmaceuticals compare to Septerna?

Is SEPN or ENTA more profitable?

Do analysts prefer SEPN or ENTA?

Does the media prefer SEPN or ENTA?

Which has more risk & volatility, SEPN or ENTA?

Do institutionals & insiders hold more shares of SEPN or ENTA?

Which has better earnings and valuation, SEPN or ENTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTA vs. The Competition

Enanta Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools